Evidence map›Paper›PMID 32301583›Full record

ArticleChemMedChem2020

A Focus on Unusual ECL2 Interactions Yields β

Magdalena M Scharf, Mirjam Zimmermann, Florian Wilhelm, Raimond Stroe, Maria Waldhoer, Peter Kolb

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Photo-clenbuterol: Optical Control of βJournal of medicinal chemistry · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Magdalena M ScharfDepartment of Pharmaceutical Chemistry, Philipps-University Marburg, Marbacher Weg 6, 35037, Marburg, Germany.ORCID 0000-0002-3305-3956
Mirjam ZimmermannInterAx Biotech, PARK innovAARE, 5234, Villigen, Switzerland.
Florian WilhelmInterAx Biotech, PARK innovAARE, 5234, Villigen, Switzerland.
Raimond StroeInterAx Biotech, PARK innovAARE, 5234, Villigen, Switzerland.
Maria WaldhoerInterAx Biotech, PARK innovAARE, 5234, Villigen, Switzerland.
Peter KolbDepartment of Pharmaceutical Chemistry, Philipps-University Marburg, Marbacher Weg 6, 35037, Marburg, Germany.ORCID 0000-0003-4089-614X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The binding pockets of aminergic G protein-coupled receptors are often targeted by drugs and virtual screening campaigns. In order to find ligands with unprecedented scaffolds for one of the best-investigated receptors of this subfamily, the β

Indexed as

Adrenergic beta-2 Receptor AntagonistsDose-Response Relationship, DrugHumansMolecular Docking SimulationMolecular StructureReceptors, Adrenergic, beta-2Structure-Activity RelationshipAdrenergic beta-2 Receptor AntagonistsReceptors, Adrenergic, beta-2beta2-adrenergic receptor ligandsdrug designG protein-coupled receptorsligand scaffoldsvirtual screening

Identifiers

PMID32301583
PMCPMC7318225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.